OVID

Ovid Therapeutics Inc

2.46

Oct 21 • 3:57 PM ET +0.10 (4.29%)

Healthcare Biotechnology USA Small NASD

Peers: XENE STOK RAPP PRAX NGNE MPLT CTNM ACAD NERV TSHA

| Held by: VTI IWM XBI VXF IWN VTWO FESM IWC VFMO ITOT

Index	RUT
Market Cap	480.68M
Enterprise Value	376.17M
Income	-34.49M
Sales	1.58M
Book/sh	1.14
Cash/sh	0.60
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	23
IPO	May 05, 2017

P/E	-
Forward P/E	-
PEG	-
P/S	304.23
P/B	2.17
P/C	4.10
P/FCF	-
EV/EBITDA	-
EV/Sales	238.08
Quick Ratio	12.39
Current Ratio	12.39
Debt/Eq	0.06
LT Debt/Eq	0.05
Option/Short	Yes / Yes

EPS (ttm)	-0.25
EPS next Y	-0.39
EPS next Q	-0.08
EPS this Y	-56.74%
EPS next Y	-6.96%
EPS next 5Y	-20.07%
EPS past 3/5Y	32.53% 29.81%
Sales past 3/5Y	68.99% -10.48%
EPS Y/Y TTM	52.86%
Sales Y/Y TTM	-76.20%
EPS Q/Q	-15.33%
Sales Q/Q	-88.31%
Earnings	Aug 13 BMO
EPS/Sales Surpr.	30.43% 3325.23%

Insider Own	7.38%
Insider Trans	0.00%
Inst Own	79.52%
Inst Trans	27.56%
ROA	-22.30%
ROE	-25.96%
ROIC	-15.60%
Gross Margin	92.92%
Oper. Margin	-3686.67%
Profit Margin	-2178.84%
SMA20	4.17%
SMA50	-5.40%
SMA200	5.19%
Trades

Shs Outstand	184.76M
Shs Float	180.88M
Short Float	10.48%
Short Ratio	11.70
Short Interest	18.95M
52W High	3.11 -20.73%
52W Low	1.18 108.58%
Volatility	7.89% 6.61%
ATR (14)	0.16
RSI (14)	52.15
Beta	0.25
Rel Volume	2.76
Avg Volume	1.62M
Volume	4,441,345

Perf Week	12.39%
Perf Month	-10.82%
Perf Quarter	2.55%
Perf Half Y	-7.47%
Perf YTD	51.00%
Perf Year	53.83%
Perf 3Y	-29.07%
Perf 5Y	-32.01%
Perf 10Y	-
Recom	1.00
Target Price	6.00
Prev Close	2.36
Price	2.46
Change %	4.29%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-15-26	Initiated	Wolfe Research	Outperform	$5
Oct-09-26	Initiated	Cantor Fitzgerald	Overweight
Oct-06-26	Initiated	Guggenheim	Buy	$7
Dec-11-25	Initiated	Roth Capital	Buy	$3
Nov-17-25	Initiated	Leerink Partners	Outperform
Oct-09-25	Initiated	Oppenheimer	Outperform	$7
Aug-08-25	Resumed	B. Riley Securities	Buy	$3
Jun-18-24	Downgrade	Oppenheimer	Outperform → Perform
Apr-30-24	Initiated	B. Riley Securities	Buy	$9
Apr-29-24	Initiated	H.C. Wainwright	Buy	$9
Apr-05-24	Initiated	Wedbush	Outperform	$8
Dec-21-23	Initiated	BTIG Research	Buy	$11
Oct-13-23	Initiated	Oppenheimer	Outperform	$8
Apr-20-21	Downgrade	Cantor Fitzgerald	Buy → Neutral	$4
Mar-03-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$5
Dec-02-20	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Dec-02-20	Downgrade	Citigroup	Buy → Neutral	$10 → $4
Sep-04-19	Initiated	RBC Capital Mkts	Outperform	$12
Apr-20-18	Initiated	Ladenburg Thalmann	Buy	$27

Show Previous Ratings

Oct-15-26 07:30AM	Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer (PR Newswire)
Sep-03-26 08:00AM	Ovid Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-13-26 08:30AM	Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results (GlobeNewswire) +6.87%
Jul-08-26 07:00AM	Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development (GlobeNewswire)
Jun-04-26 07:00AM	Ovid Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
07:00AM	Loading…
Jun-03-26 07:00AM	Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors (GlobeNewswire)
May-12-26 07:00AM	Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results (GlobeNewswire)
Apr-08-26 08:00AM	Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14 (GlobeNewswire)
Mar-18-26 06:05AM	Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire) +14.43%
06:00AM	Ovid Therapeutics Announces Pricing of $60 Million Private Placement (GlobeNewswire)
Mar-04-26 05:35PM	Niagen Bioscience (NAGE) Tops Q4 Earnings and Revenue Estimates (Zacks) +10.12%
Feb-25-26 07:00AM	Ovid Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.28%
Feb-19-26 07:00PM	PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Feb-13-26 03:00AM	Ovid takes another big swing in neuroscience under a new CEO (Pharma Voice) -5.33%
Jan-30-26 02:58PM	Is Ovid Therapeutics (OVID) One of the Best Fast Growing Penny Stocks to Buy According to Analysts? (Insider Monkey)
08:00AM	Loading…
Dec-18-25 08:00AM	Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) (GlobeNewswire) -9.46%
Dec-02-25 07:00AM	Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer (GlobeNewswire) -13.33%
Nov-12-25 08:10AM	Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results (GlobeNewswire)
05:20AM	Metagenomi, Ovid CEOs step aside; Cogent soars on unprecedented stomach cancer data (BioPharma Dive)
Nov-05-25 09:15AM	MannKind (MNKD) Tops Q3 Earnings and Revenue Estimates (Zacks)
Nov-04-25 05:50PM	AnaptysBio, Inc. (ANAB) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
10:00AM	Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-26-25 06:05AM	B. Riley Lifts Ovid Therapeutics (OVID) PT to $5 on Strong OV329 Phase 1 Data (Insider Monkey)
Oct-20-25 09:16AM	Take the Zacks Approach to Beat the Market: UnitedHealth, Ovid, Micron in Focus (Zacks) +11.49%
Oct-10-25 10:27AM	OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data (Zacks)
Oct-06-25 12:00PM	Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should Know (Zacks)
Oct-03-25 07:05AM	Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds (GlobeNewswire) +12.20%
07:00AM	Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile (GlobeNewswire)
Aug-23-25 04:12AM	Lucid Capital Initiates Ovid Therapeutics Inc. (OVID) at Buy with $5.50 Target (Insider Monkey)
09:25AM	Loading…
Aug-13-25 09:25AM	Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +56.86%
08:00AM	Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-25-25 12:22PM	Ovid Therapeutics Sells Ganaxolone Royalty Rights for $7M to Immedica Pharma (Insider Monkey) -10.75%
Jul-23-25 08:30AM	Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference (GlobeNewswire)
Jun-25-25 08:00AM	Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties (GlobeNewswire)
Jun-20-25 02:25PM	Are These 2 'Strong Buy' Rated Growth Stocks Buys Right Now? (Barchart)
Jun-05-25 07:30AM	Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025 (GlobeNewswire)
May-13-25 09:15AM	Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -5.30%
08:00AM	Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results (GlobeNewswire)
May-12-25 07:50AM	Fortrea Holdings Inc. (FTRE) Q1 Earnings and Revenues Beat Estimates (Zacks)
May-09-25 08:10AM	ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates (Zacks)
May-06-25 05:20PM	Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates (Zacks) -5.87%
10:00AM	Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
May-01-25 07:40AM	Moderna (MRNA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Apr-29-25 08:15AM	Incyte (INCY) Q1 Earnings and Revenues Top Estimates (Zacks)
Apr-02-25 08:00AM	Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) +9.78%
Mar-11-25 09:10AM	Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-03-25 08:00AM	Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors (GlobeNewswire) -6.92%
Feb-27-25 08:00AM	Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-05-25 08:00AM	Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire) +5.04%
Jan-30-25 09:55AM	Ovid Therapeutics upgraded at Oppenheimer as OV329s promise quite real (TipRanks) -5.57%
Dec-02-24 08:00AM	Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting (GlobeNewswire)
Nov-12-24 09:30AM	Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -8.82%
08:00AM	Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-31-24 08:00AM	Ovid Therapeutics to Host Investor Event (GlobeNewswire)
Sep-26-24 08:00AM	Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin (GlobeNewswire)
Sep-20-24 04:00AM	After epilepsy setback, Ovid charges confidently ahead in CNS (Pharma Voice)
Sep-11-24 08:00AM	Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth (GlobeNewswire)
Sep-04-24 08:00AM	Ovid Therapeutics to Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-20-24 12:00PM	Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why (Zacks)
Aug-13-24 09:10AM	Ovid Therapeutics (OVID) Q2 Earnings and Revenues Surpass Estimates (Zacks)
08:00AM	Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results (GlobeNewswire)
07:00AM	Lilly opens R&D hub; Ovid and Lexicon lay off staff (BioPharma Dive)
Aug-08-24 08:00AM	Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer (GlobeNewswire)
Jul-30-24 08:00AM	Ovid Therapeutics to Present at Upcoming August Investor Conferences (GlobeNewswire)
Jul-23-24 08:00AM	Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists (GlobeNewswire)
Jul-22-24 07:00AM	7 Sorry Biotech Stocks Set to Make Investors Sad (InvestorPlace)
Jul-15-24 10:45AM	Ovid Therapeutics Inc. (OVID): One of the Best Penny Stocks to Buy Under $1 According to Hedge Funds? (Insider Monkey)
09:35AM	10 Best Penny Stocks to Buy Under $1 (Insider Monkey)
Jul-10-24 08:00AM	eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures (GlobeNewswire) +5.31%
Jul-01-24 08:00AM	Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations (GlobeNewswire) +12.09%
Jun-18-24 09:51AM	Apple downgraded, Kroger upgraded: Wall Street's top analyst calls (The Fly)
Jun-17-24 01:45PM	Is the Stock Market Closed on Juneteenth 2024? (InvestorPlace) -76.00%
01:28PM	ACHR Stock Alert: Archer Aviation Strikes New Deal With Signature Aviation (InvestorPlace)
01:03PM	AAN Stock Alert: The Aaron's Company Pops 33% on Take-Private Deal (InvestorPlace)
12:38PM	Why Is Ovid Therapeutics (OVID) Stock Down 69% Today? (InvestorPlace)
08:07AM	Takeda drug for rare types of epilepsy misses goal in late-stage trial (BioPharma Dive)
06:55AM	Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat (GlobeNewswire)
May-28-24 01:09PM	3 Sorry Penny Stocks to Sell in May While You Still Can (InvestorPlace)
May-20-24 06:00AM	Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for May 2024 (InvestorPlace)
May-14-24 01:54PM	OVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +6.95%
09:10AM	Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results (GlobeNewswire)
May-13-24 07:00AM	Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire)
Apr-30-24 07:23AM	B. Riley Securities Initiates Ovid Therapeutics With Buy Rating, $9 Price Target (MT Newswires) -8.68%
Apr-29-24 07:18AM	HC Wainwright Starts Ovid Therapeutics With Buy Rating, $9 Price Target (MT Newswires) +7.74%
Apr-26-24 10:00AM	Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-04-24 08:00AM	Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-17-24 05:19PM	5 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
Mar-08-24 08:00AM	Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-28-24 08:00AM	Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire) -5.51%
Feb-06-24 08:00AM	Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Dec-01-23 07:30AM	Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023) (GlobeNewswire) +7.39%
Nov-09-23 12:00PM	Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why (Zacks) -5.65%
08:48AM	Q3 2023 Ligand Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-05-23 07:15PM	Ovid Therapeutics Inc (OVID) Reports Q3 2023 Financial Results (GuruFocus.com)
Nov-03-23 08:00AM	Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire)
Oct-19-23 10:44AM	These 2 Strong Buy Penny Stocks Have Massive Upside Potential, Says Oppenheimer (TipRanks)
Oct-18-23 08:00AM	Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026 (GlobeNewswire) -7.13%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jeffrey A. Rona	Affiliated Stockholder	Aug 24 '26	Proposed Sale	2.80	325,000	910,000		Aug 24 04:47 PM
Jeffrey A. Rona	Affiliated Stockholder	Aug 14 '26	Proposed Sale	2.80	150,000	420,000		Aug 14 06:27 PM
LEVIN JEREMY M	Executive Chairman	Mar 23 '26	Option Exercise	1.40	47,333	66,266	3,735,048	Mar 25 09:18 PM
ALEXANDER MARGARET A.	President and CEO	Feb 23 '26	Sale	1.45	11,656	16,901	61,750	Mar 02 04:30 PM
Rona Jeffrey A	CBFO	Feb 23 '26	Sale	1.45	8,541	12,384	88,188	Mar 02 04:30 PM

Ovid Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering better, gentler medicines for the brain. It discovers and develops differentiated, small molecule medicines for neurological and neuropsychiatric disorders with significant unmet need. The company was founded by Matthew During and Jeremy M. Levin on April 1, 2014 and is headquartered in New York, NY.

DphilDr. Jeremy Max Levin Ba Zoology

CEOMs. Margaret Alexander

AdvisorMr. Jeffrey A. Rona

M.S.Mr. Charles Ross Carter M.B.A.

Chief Scientific OfficerDr. Zhong Zhong Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OVID

Ovid Therapeutics Inc

Upgrade your Finviz experience